Skip to main content
Premium Trial:

Request an Annual Quote

Inproteo Subsidiary Prosolia Licenses Electrospray Technology to Thermo Electron

NEW YORK, Sept. 7 (GenomeWeb News) - Prosolia, a subsidiary of Inproteo, today announced that it has agreed to license its ElectroSonicSpray Ionization technology to Thermo Electron. Financial terms of the deal were not disclosed.

 

The ESSI technology is a proprietary ionization technique that enables ionization of large molecules such as protein and protein complexes, while retaining their conformation and function, Prosolia said.

 

Ian Jardine, Thermo Electron's chief technology officer, said in an official statement that Thermo would likely commercially implement the technology in early 2005 to complement the current technique of electrospray ionization and MALDI for analyzing large biological molecules.

The Scan

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.